Distinguishing Between Off-Label Guidelines for Device vs. Pharmaceutical Companies
July 14, 2010
David Rosen will present, “Distinguishing Between Off-Label Guidelines for Device vs. Pharmaceutical Companies” at the ACI 7th National Forum on Off-Label Communications, July 14-15, 2010 at the Union League, in Philadelphia.
Speakers will cover compliance strategies with FDA off-label promotion guidelines, training physicians on the use of medical devices, and learning from device manufacturers’ litigation. Thomas Lynch, Senior Corporate Counsel at Boston Scientific will join Mr. Rosen as a speaker.
More information can be found on ACI’s Web site.
People
Related Insights
July 9, 2025
Foley Viewpoints
SEC and CFTC Extend Form PF Compliance Date Again
On June 11, 2025 the Securities and Exchange Commission (SEC) and Commodity Futures Trading Commission (CFTC) again extended the…
July 9, 2025
Foley Viewpoints
Trump Accounts: The New Child Savings Account Established Under the One Big Beautiful Bill Act
On July 4, 2025, President Trump signed into law the One Big Beautiful Bill Act (OBBA). The OBBA established a new type of tax-advantaged…
July 9, 2025
Foley Viewpoints
One Big Beautiful Bill Act Permanently Increases the Lifetime Estate, Gift and GST Tax Exclusion
On July 4, 2025, President Trump signed into law the One Big Beautiful Bill Act (OBBBA). The OBBBA extended and may permanent many key…